Skip to content

BCBS Minnesota

Does BCBS Minnesota cover Wegovy?

It depends on your benefits. BCBS Minnesota covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • BCBS Minnesota Employer / Commercial Insurance prior authorization policy

    BCBS Minnesota · PA policy · Employer

    Effective April 1, 2026. Verified June 5, 2026.

    View PDF Download Original insurer source
  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Weight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.

Qualification pathways

You can qualify through any one of these.

Adult Weight Management

All of:

  • Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
  • Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
  • Patient is an adult (18 years of age or over)
  • Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
  • Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
  • Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient's age is within FDA labeling OR there is support for use at patient's age
  • Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

  • BMI ≥ 30 kg/m2
  • BMI ≥ 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
  • BMI ≥ 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)

Pediatric Weight Management (12-17 years)

All of:

  • Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
  • Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
  • Patient is pediatric (12 to 17 years of age)
  • Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
  • Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
  • Patient will NOT use the requested agent in combination with another weight loss agent
  • Patient is currently on and will continue weight management regimen
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications
  • Patient's age is within FDA labeling OR there is support for use at patient's age
  • Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

  • BMI ≥ 95th percentile for age and sex
  • BMI ≥ 30 kg/m2
  • BMI ≥ 85th percentile for age and sex AND at least one severe weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)

Repeat Course of Therapy (prior weight loss agent in past 12 months)

All of:

  • Patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months
  • Prescriber anticipates success with repeating therapy with any targeted weight loss agent
  • All other standard weight management criteria met

Documentation to bring

  • Documentation of BMI (≥ 30 kg/m2, or ≥ 27 kg/m2 with comorbidity, or ≥ 25 kg/m2 if South/Southeast/East Asian)
  • Documentation of 6-month weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
  • Documentation of weight loss less than 1 pound per week on weight management regimen prior to pharmacotherapy
  • Documentation that weight loss is not excluded from coverage under the patient's pharmacy benefit
  • Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful
  • For pediatric patients: documentation of age (12-17), BMI percentile for age and sex, and qualifying comorbidities if applicable
  • For repeat course: documentation of prior targeted weight loss agent use and prescriber attestation of anticipated success

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At least 5% reduction in BMI.
  • Renewal: For adults: weight loss ≥ 5% from baseline (prior to initiation of pharmacotherapy). For pediatric (12-17): BMI reduction ≥ 5% from baseline. Exception: if patient has received less than 52 weeks of therapy on the maximum-tolerated dose, continuation is approved without the weight loss threshold. Renewal also requires dose be 1.7 mg, 2.4 mg, or 25 mg. Patient must maintain diet/exercise/behavioral modification regimen and not combine with another weight loss agent or GLP-1.
  • Renewal: At least 52 weeks on therapy before the first renewal.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical) is not permitted
  • Co-administration with another GLP-1 receptor agonist is not permitted
  • Any FDA labeled contraindications to the requested agent
  • Weight loss coverage excluded from pharmacy benefit

Policy note: Policy applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies. Weight loss agents on coverage delay apply to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open. For the 6-month lifestyle program, the patient must not have lost ≥ 1 lb/week (i.e., inadequate response to lifestyle). The initial approval criteria for Wegovy weight loss specifically include continuation milestones embedded: starting therapy or < 52 weeks of therapy are eligible without weight loss threshold; ≥ 52 weeks requires ≥ 5% weight loss. Prior targeted weight loss agent (Saxenda, Wegovy, Zepbound) use in the past 12 months does not automatically disqualify but requires prescriber attestation. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Expanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction — Initial Approval

All of:

  • Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
  • Requested agent is FDA labeled for the requested indication and route of administration (Wegovy)
  • Patient has a BMI ≥ 27 kg/m2
  • Patient does NOT have type 2 diabetes
  • Patient's age is 45 years or over
  • Patient is currently being treated in the past 90 days with antihypertensive therapy (ACE inhibitor, ARB, or beta blocker)
  • Patient is currently being treated in the past 90 days with lipid lowering therapy (any statin or ezetimibe)
  • Patient will continue antihypertensive therapy AND lipid lowering therapy in combination with the requested agent
  • Prescriber is a specialist (e.g., cardiologist) or has consulted with a specialist
  • Patient will NOT use the requested agent in combination with another weight loss agent
  • Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications
  • Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

  • History of myocardial infarction
  • History of stroke
  • Peripheral artery disease defined by intermittent claudication with ankle-brachial index < 0.85 at rest, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Tobacco Use Requirement

Plus any one of:

  • Patient does NOT currently use any tobacco products (cigarettes, chewing tobacco)
  • Patient is being managed for tobacco cessation

Documentation to bring

  • Medical records documenting established cardiovascular disease (CAD, ACS, history of MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid or arterial stenosis, PAD including aortic aneurysm, all of atherosclerotic origin)
  • Medical records confirming qualifying CV event: MI, stroke, or PAD (intermittent claudication with ABI < 0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease)
  • Documentation of BMI ≥ 27 kg/m2
  • Documentation that patient does NOT have type 2 diabetes
  • Documentation that patient is age 45 or over
  • Documentation of current antihypertensive therapy (ACE inhibitor, ARB, or beta blocker) within past 90 days
  • Documentation of current lipid-lowering therapy (statin or ezetimibe) within past 90 days
  • Documentation of tobacco use status or active tobacco cessation management
  • Documentation of specialist involvement (cardiologist) or consultation
  • Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At renewal: patient must have clinical benefit with the requested agent. CV qualifying event and T2DM exclusion are re-verified at renewal. GDMT requirement at renewal is slightly relaxed: patient must be treated with antihypertensive therapy AND/OR lipid-lowering therapy (initial approval requires BOTH antihypertensive AND lipid-lowering therapy). Tobacco cessation requirement is re-verified. Specialist requirement is re-verified.

Not covered when

  • Type 2 diabetes (explicitly excluded — this indication requires absence of T2DM)
  • Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Co-administration with another GLP-1 receptor agonist
  • Any FDA labeled contraindications

Policy note: Established CVD is broadly defined in this policy to include: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm (all of atherosclerotic origin). However, for the qualifying CV event (criteria #3), only MI, stroke, or PAD (as specifically defined) qualify. At renewal, GDMT requirement is slightly relaxed from 'both antihypertensive AND lipid-lowering' to 'antihypertensive AND/OR lipid-lowering.' Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Expanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.

Qualification pathways

You can qualify through any one of these.

MASH with F2-F3 Fibrosis — Initial Approval

All of:

  • Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
  • Diagnosis of noncirrhotic MASH (formerly NASH) with moderate to advanced liver fibrosis (stages F2 to F3)
  • Requested agent is Wegovy injection
  • Patient is an adult (18 years of age or over)
  • Stage F2 or F3 fibrosis confirmed by one of: liver biopsy, VCTE (e.g., FibroScan), ELF score, or MRE (prior to therapy)
  • Patient is being monitored and/or treated for any comorbid conditions (e.g., cardiovascular disease, diabetes, dyslipidemia, hypertension)
  • Patient does NOT have decompensated cirrhosis
  • Patient does NOT have moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Patient does NOT have any other liver disease (e.g., Wilson's disease, HCC, hepatitis)
  • Prescriber is a specialist (e.g., hepatologist, gastroenterologist) or has consulted with a specialist
  • Patient will NOT use the requested agent in combination with another weight loss agent
  • Patient is currently on and will continue weight management regimen
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications
  • Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

  • Female patient with alcohol consumption less than 20 grams/day
  • Male patient with alcohol consumption less than 30 grams/day

Documentation to bring

  • Medical records documenting diagnosis of noncirrhotic MASH with fibrosis stages F2 or F3
  • Documentation of fibrosis staging confirmed by liver biopsy, VCTE (FibroScan), ELF score, or MRE (obtained prior to therapy initiation)
  • Documentation of alcohol consumption (< 20 g/day for females; < 30 g/day for males)
  • Documentation of monitoring/treatment for comorbid conditions (CVD, diabetes, dyslipidemia, hypertension)
  • Documentation ruling out decompensated cirrhosis, Child-Pugh Class B or C hepatic impairment, and other liver diseases (Wilson's disease, HCC, hepatitis)
  • Documentation of specialist involvement (hepatologist or gastroenterologist) or consultation
  • Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At renewal: patient must have clinical benefit with the requested agent. Alcohol limits (< 20 g/day female, < 30 g/day male) are re-verified. Exclusions for decompensated cirrhosis, Child-Pugh B/C, and other liver disease are re-verified. Specialist requirement is re-verified. Fibrosis staging confirmation (liver biopsy/VCTE/ELF/MRE) is NOT re-required at renewal.

Not covered when

  • Decompensated cirrhosis
  • Moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
  • Co-administration with another weight loss agent
  • Co-administration with another GLP-1 receptor agonist
  • Any FDA labeled contraindications
  • Alcohol consumption ≥ 20 g/day (female) or ≥ 30 g/day (male)

Policy note: The MASH indication is an expanded indication. Fibrosis must be stage F2 or F3 (noncirrhotic). Fibrosis confirmation methods accepted: liver biopsy, VCTE (FibroScan), ELF score, or MRE — no lookback period explicitly stated in the policy. The policy does not explicitly state a FIB-4 score as a standalone qualifying confirmation method (though it is discussed in the clinical rationale). The policy requires monitoring/treatment of comorbidities. Alcohol limits align with MASLD definition: < 20 g/day female, < 30 g/day male. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

BCBS Minnesota has separate Wegovy policies that don't depend on that benefit:

Questions people ask
Does BCBS Minnesota cover Wegovy?
It depends on your benefits. BCBS Minnesota covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Wegovy approval last with BCBS Minnesota?
Weight Loss — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months. Liver Disease (MASH) — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Minnesota require to renew Wegovy?
Weight Loss — Applies to Employer plans. At least 5% reduction in BMI. For adults: weight loss ≥ 5% from baseline (prior to initiation of pharmacotherapy). For pediatric (12-17): BMI reduction ≥ 5% from baseline. Exception: if patient has received less than 52 weeks of therapy on the maximum-tolerated dose, continuation is approved without the weight loss threshold. Renewal also requires dose be 1.7 mg, 2.4 mg, or 25 mg. Patient must maintain diet/exercise/behavioral modification regimen and not combine with another weight loss agent or GLP-1. At least 52 weeks on therapy before the first renewal. Staying on a maintenance dose of at least 1.7 mg. Heart Disease Risk Reduction — Applies to Employer plans. At renewal: patient must have clinical benefit with the requested agent. CV qualifying event and T2DM exclusion are re-verified at renewal. GDMT requirement at renewal is slightly relaxed: patient must be treated with antihypertensive therapy AND/OR lipid-lowering therapy (initial approval requires BOTH antihypertensive AND lipid-lowering therapy). Tobacco cessation requirement is re-verified. Specialist requirement is re-verified. Liver Disease (MASH) — Applies to Employer plans. At renewal: patient must have clinical benefit with the requested agent. Alcohol limits (< 20 g/day female, < 30 g/day male) are re-verified. Exclusions for decompensated cirrhosis, Child-Pugh B/C, and other liver disease are re-verified. Specialist requirement is re-verified. Fibrosis staging confirmation (liver biopsy/VCTE/ELF/MRE) is NOT re-required at renewal.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Minnesota: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Minnesota Medicaid, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Minnesota's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.